Evidence map›Paper›PMID 40862973›Full record

ReviewBiosensors2025

Gut Feeling: Biomarkers and Biosensors' Potential in Revolutionizing Inflammatory Bowel Disease (IBD) Diagnosis and Prognosis-A Comprehensive Review.

Beatriz Teixeira, Helena M R Gonçalves, Paula Martins-Lopes

Abstract readReview
In one paragraph

Review in Biosensors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Observational
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Beatriz TeixeiraDNA & RNA Sensing Lab, Department of Genetics and Biotechnology, Universidade de Trás-os-Montes e Alto Douro, 5000-901 Vila Real, Portugal.ORCID 0000-0001-9194-5779
Helena M R GonçalvesLAQV, REQUIMTE, Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, 4099-002 Porto, Portugal.ORCID 0000-0001-6210-8736
Paula Martins-LopesDNA & RNA Sensing Lab, Department of Genetics and Biotechnology, Universidade de Trás-os-Montes e Alto Douro, 5000-901 Vila Real, Portugal.ORCID 0000-0001-8229-0117

Funding

Fundação da Ciência e Tecnologia 10.54499/2022.04199.CEECIND/CP1724/CT0008Fundação da Ciência e Tecnologia UID/50006/2025Fundação da Ciência e Tecnologia UIDB/04046/2020
6 · The paper itself

Abstract

Inflammatory Bowel Diseases (IBDs) are complex, multifactorial disorders with no known cure, necessitating lifelong care and often leading to surgical interventions. This ongoing healthcare requirement, coupled with the increased use of biological drugs and rising disease prevalence, significantly increases the financial burden on the healthcare systems. Thus, a number of novel technological approaches have emerged in order to face some of the pivotal questions still associated with IBD. In navigating the intricate landscape of IBD, biosensors act as indispensable allies, bridging the gap between traditional diagnostic methods and the evolving demands of precision medicine. Continuous progress in biosensor technology holds the key to transformative breakthroughs in IBD management, offering more effective and patient-centric healthcare solutions considering the One Health Approach. Here, we will delve into the landscape of biomarkers utilized in the diagnosis, monitoring, and management of IBD. From well-established serological and fecal markers to emerging genetic and epigenetic markers, we will explore the role of these biomarkers in aiding clinical decision-making and predicting treatment response. Additionally, we will discuss the potential of novel biomarkers currently under investigation to further refine disease stratification and personalized therapeutic approaches in IBD. By elucidating the utility of biosensors across the spectrum of IBD care, we aim to highlight their importance as valuable tools in optimizing patient outcomes and reducing healthcare costs.

Indexed as

BiomarkersBiosensing TechniquesInflammatory Bowel DiseasesHumansPrognosisBiomarkersbiomarkersbiosensorsdiagnosisIBDprognosis

Identifiers

PMID40862973
PMCPMC12384142

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.